Company Description
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally.
The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.
It also develops, manufactures, and sells active pharmaceutical ingredients.
In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas.
Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease.
The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease.
Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim.
Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia.
The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
Country | IL |
IPO Date | Feb 16, 1982 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 37,000 |
CEO | Richard D. Francis |
Contact Details
Address: 124 Dvora Hanevi'a Street Tel Aviv, IL | |
Website | https://www.tevapharm.com |
Stock Details
Ticker Symbol | TEVA |
Exchange | NYSE |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000818686 |
CUSIP Number | 881624209 |
ISIN Number | US8816242098 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Richard D. Francis | President, Chief Executive Officer & Director |
David R. Mcavoy J.D. | Executive Vice President & Chief Legal Officer |
Eliyahu Sharon Kalif | Executive Vice President & Chief Financial Officer |
Amir Weiss | Senior Vice President & Chief Accounting Officer |
Kathleen Veit | Senior Vice President, Global Compliance & Ethics Officer |
Mark Sabag | Executive Vice President of International Markets Commercial |
Matthew Shields | Executive Vice President of Global Operations |
Placid Jover | Executive Vice President & CHRO |
Ran Meir | Head of Investor Relations |
Richard Gordon Daniell | Executive Vice President of European Commercial |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 04, 2024 | 4 | Filing |
Dec 04, 2024 | 3 | Filing |
Nov 21, 2024 | 4 | Filing |
Nov 12, 2024 | 8-K | Current Report |
Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
Nov 06, 2024 | 10-Q | Quarterly Report |
Nov 06, 2024 | 8-K | Current Report |
Sep 04, 2024 | 4 | Filing |
Aug 13, 2024 | 4 | Filing |
Aug 13, 2024 | 4 | Filing |